NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
Clinical Trials
67 trialsNCT04921358 2025-06-29
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
BeiGene
Phase 3 Terminated
NCT04427072 2025-05-16
GeoMETry-III
Novartis
Phase 3 Terminated
NCT05543629 2025-03-18
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT05062980 2025-02-20
Acclaim-2
Genprex, Inc.
Phase 1/2 Terminated
NCT02231164 2025-02-13
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
Boehringer Ingelheim
Phase 3 Terminated
NCT05084859 2024-08-09
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Biosplice Therapeutics, Inc.
Phase 1 Terminated
NCT03095612 2024-06-13
Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT04171284 2024-02-09
SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer
Sinocelltech Ltd.
Phase 3 Terminated
NCT00617656 2024-01-30
BREC
Spanish Lung Cancer Group
Phase 3 Terminated
NCT03228186 2023-10-23
Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT03626545 2023-08-21
CANOPY-2
Novartis
Phase 3 Terminated
NCT04863248 2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT02460367 2022-04-06
Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
Lumos Pharma
Phase 1 Terminated
NCT03990077 2021-12-10
Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
Shanghai Kechow Pharma, Inc.
Phase 1 Terminated
NCT04165031 2021-11-24
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
Phase 1/2 Terminated
NCT01741155 2021-10-13
Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT02387216 2021-10-12
SHERLOC
Elevation Oncology
Phase 2 Terminated
NCT03256721 2021-02-08
Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC
Fuzhou General Hospital
Phase 2 Terminated
NCT00738387 2020-12-24
ATTRACT-2
Novartis
Phase 3 Terminated
NCT01774578 2020-05-28
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Lumos Pharma
Phase 2/3 Terminated
NCT02117024 2020-02-05
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Heat Biologics
Phase 2 Terminated
NCT02322281 2019-08-14
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Clovis Oncology, Inc.
Phase 3 Terminated
NCT01646125 2019-07-24
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
Novartis
Phase 2 Terminated
NCT02775006 2019-04-30
Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma
The Netherlands Cancer Institute
Phase 3 Terminated
NCT02346370 2019-02-08
PRIMAL
Halozyme Therapeutics
Phase 1 Terminated
NCT01935947 2018-07-27
Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02393209 2018-02-07
Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Takeda
Phase 1/2 Terminated
NCT02326285 2018-01-23
NeoIntercal
AIO-Studien-gGmbH
Phase 2/3 Terminated
NCT00356941 2017-11-29
Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00801801 2017-05-17
Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC
University of Alabama at Birmingham
Phase 2 Terminated
NCT00520845 2017-03-20
Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00565227 2016-12-02
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT01798485 2016-07-01
Galaxy 2
Synta Pharmaceuticals Corp.
Phase 3 Terminated
NCT00766246 2016-04-19
Phase II Avastin Trial for Stage IIIB/IV NSCLC
Pharmatech
Phase 2 Terminated
NCT01348126 2015-11-05
GALAXY
Synta Pharmaceuticals Corp.
Phase 2/3 Terminated
NCT00391586 2015-08-17
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT01282151 2015-07-14
TRAIL
Chonnam National University Hospital
Phase 3 Terminated
NCT00378404 2015-06-08
Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC
University of Kentucky
Phase 1 Terminated
NCT01038752 2015-05-21
Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer
Optimum Therapeutics, LLC
Phase 2 Terminated
NCT00238615 2015-05-12
Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC
Stanford University
Phase 2 Terminated
NCT01714037 2015-04-08
HALO
Debiopharm International SA
Phase 1 Terminated
NCT00633568 2015-02-12
Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer
European Lung Cancer Working Party
Phase 3 Terminated
NCT00511576 2015-01-08
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Mirati Therapeutics Inc.
Phase 1 Terminated
NCT02127372 2014-09-15
Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571
Duke University
Phase 1/2 Terminated
NCT00509366 2014-08-28
TOP0602
Duke University
Phase 2 Terminated
NCT02157116 2014-07-04
Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer
Duke University
Phase 2 Terminated
NCT00145418 2014-06-30
Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer
Oncology Specialists, S.C.
Phase 2 Terminated
NCT00088933 2014-03-31
Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01356368 2014-01-22
Customizing
National Guard Health Affairs
Phase 2 Terminated